Cellis is developing Macrophage Drug Conjugates (MDCs) which is a breakthrough, new class of therapy for solid tumors. Cellis uses allogeneic macrophages conjugated with therapeutic medications for treatment of several solid tumors. Our focus is on glioblastoma, ovarian and pancreatic cancer.

Some insights
Facts & figures
  • Type of organization
    Private company
  • Number of employees in Switzerland
Key business
Core competencies